vs
HBT Financial, Inc.（HBT）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
HBT Financial, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.9倍（$67.3M vs $35.5M），HBT Financial, Inc.净利率更高（16.6% vs -304.2%，领先320.9%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 9.0%）
HBT Financial, Inc.是总部位于美国伊利诺伊州的区域性银行控股公司，主要为运营区域内的社区居民、中小微企业提供各类零售及商业银行业务，涵盖存取款服务、消费及商业信贷、财富管理咨询、按揭贷款等金融产品。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
HBT vs RXRX — 直观对比
营收规模更大
HBT
是对方的1.9倍
$35.5M
净利率更高
HBT
高出320.9%
-304.2%
两年增速更快
RXRX
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $67.3M | $35.5M |
| 净利润 | $11.2M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 16.6% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | -41.3% | 39.6% |
| 每股收益（稀释后） | $0.34 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HBTRXRX
| Q1 26 | $67.3M | — | ||
| Q4 25 | $60.4M | $35.5M | ||
| Q3 25 | $59.8M | $5.2M | ||
| Q2 25 | $58.8M | $19.2M | ||
| Q1 25 | $58.0M | $14.7M | ||
| Q4 24 | $59.0M | $4.5M | ||
| Q3 24 | $56.4M | $26.1M | ||
| Q2 24 | $56.6M | $14.4M |
净利润HBTRXRX
| Q1 26 | $11.2M | — | ||
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $19.8M | $-162.3M | ||
| Q2 25 | $19.2M | $-171.9M | ||
| Q1 25 | $19.1M | $-202.5M | ||
| Q4 24 | $20.3M | $-178.9M | ||
| Q3 24 | $18.2M | $-95.8M | ||
| Q2 24 | $18.1M | $-97.5M |
毛利率HBTRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
营业利润率HBTRXRX
| Q1 26 | — | — | ||
| Q4 25 | 42.9% | -304.8% | ||
| Q3 25 | 44.7% | -3327.6% | ||
| Q2 25 | 44.8% | -916.8% | ||
| Q1 25 | 44.0% | -1297.9% | ||
| Q4 24 | 46.4% | -4042.4% | ||
| Q3 24 | 43.4% | -377.1% | ||
| Q2 24 | 44.1% | -697.4% |
净利率HBTRXRX
| Q1 26 | 16.6% | — | ||
| Q4 25 | — | -304.2% | ||
| Q3 25 | 33.0% | -3135.3% | ||
| Q2 25 | 32.7% | -894.2% | ||
| Q1 25 | 32.9% | -1373.3% | ||
| Q4 24 | 42.8% | -3935.5% | ||
| Q3 24 | 32.2% | -367.5% | ||
| Q2 24 | 31.9% | -676.6% |
每股收益（稀释后）HBTRXRX
| Q1 26 | $0.34 | — | ||
| Q4 25 | $0.60 | $-0.17 | ||
| Q3 25 | $0.63 | $-0.36 | ||
| Q2 25 | $0.61 | $-0.41 | ||
| Q1 25 | $0.60 | $-0.50 | ||
| Q4 24 | $0.64 | $-0.56 | ||
| Q3 24 | $0.57 | $-0.34 | ||
| Q2 24 | $0.57 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $287.7M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $747.4M | $1.1B |
| 总资产 | $6.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资HBTRXRX
| Q1 26 | $287.7M | — | ||
| Q4 25 | $122.3M | $743.3M | ||
| Q3 25 | $155.1M | $659.8M | ||
| Q2 25 | $195.7M | $525.1M | ||
| Q1 25 | $211.6M | $500.5M | ||
| Q4 24 | $137.7M | $594.4M | ||
| Q3 24 | $179.7M | $427.6M | ||
| Q2 24 | $195.2M | $474.3M |
总债务HBTRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M |
股东权益HBTRXRX
| Q1 26 | $747.4M | — | ||
| Q4 25 | $615.5M | $1.1B | ||
| Q3 25 | $599.1M | $1.0B | ||
| Q2 25 | $580.9M | $919.1M | ||
| Q1 25 | $565.1M | $933.9M | ||
| Q4 24 | $544.6M | $1.0B | ||
| Q3 24 | $537.7M | $524.6M | ||
| Q2 24 | $509.5M | $584.4M |
总资产HBTRXRX
| Q1 26 | $6.8B | — | ||
| Q4 25 | $5.1B | $1.5B | ||
| Q3 25 | $5.0B | $1.4B | ||
| Q2 25 | $5.0B | $1.3B | ||
| Q1 25 | $5.1B | $1.3B | ||
| Q4 24 | $5.0B | $1.4B | ||
| Q3 24 | $5.0B | $726.5M | ||
| Q2 24 | $5.0B | $775.9M |
负债/权益比HBTRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流HBTRXRX
| Q1 26 | — | — | ||
| Q4 25 | $85.1M | $-46.1M | ||
| Q3 25 | $17.2M | $-117.4M | ||
| Q2 25 | $13.6M | $-76.4M | ||
| Q1 25 | $30.4M | $-132.0M | ||
| Q4 24 | $89.4M | $-115.4M | ||
| Q3 24 | $25.5M | $-59.2M | ||
| Q2 24 | $19.8M | $-82.2M |
自由现金流HBTRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M |
自由现金流率HBTRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% |
资本支出强度HBTRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% |
现金转化率HBTRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.87× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 1.60× | — | ||
| Q4 24 | 4.41× | — | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 1.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HBT
| Net Interest Income | $56.4M | 84% |
| Noninterest Income | $10.9M | 16% |
RXRX
暂无分部数据
